Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Lexicon Pharmaceuticals, Inc. reported revenue of $50M, up 60.2% year over year. Operating margin was -98.2% and net margin -101.1%, on a free-cash-flow margin of -136.2% with capital expenditure at 0.0% of revenue. Every figure is computed directly from LXRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $50M | -98.2% | -101.1% |
| FY2024 | $31M | -634.2% | -644.8% |
| FY2023 | $1M | -14265.0% | -14710.9% |
| FY2022 | $0M | -72489.2% | -73341.0% |
| FY2021 | $0M | -29224.8% | -29449.0% |
How does LXRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.